MEIP MEI Pharma, Inc.

1.59
+0  (3%)
Previous Close 1.55
Open 1.54
Price To book 1.04
Market Cap 58.47M
Shares 36,772,000
Volume 58,048
Short Ratio 0.38
Av. Daily Volume 202,385

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data due mid-2017.
ME-401
Chronic lymphocytic leukemia/small lymphocytic lymphoma or follicular lymphoma
Phase 2 trial to commence 2Q 2017.
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 topline data released late March 2015 did not meet primary endpoint
Pracinostat in combination with Vidaza
First line intermediate-2 or high-risk Myelodysplastic Syndrome
Ongoing
Pracinostat and Vidaza or Dacogen
Myelodysplastic Syndrome
Phase 3 is planned for 1H 2017.
Pracinostat in combination with Vidaza
Elderly patients with newly diagnosed acute myeloid leukemia (AML)

Latest News

  1. MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
  2. MEI Pharma to Present at Needham Healthcare Conference
  3. MEI Pharma to Present at Oppenheimer Healthcare Conference
  4. Post Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta
  5. How MEI Pharma Inc (MEIP) Stacks Up Against Its Peers
  6. Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
  7. MEI Pharma to Host Annual Meeting of Stockholders
  8. MEI Pharma Reports First Quarter Fiscal Year 2017 Results
  9. MEI Pharma to Present at Stifel Healthcare Conference
  10. Blog Coverage MEI Pharma and Helsinn Group Announced Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia
  11. Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting
  12. MEI Pharma to Present at Wedbush PacGrow Healthcare Conference
  13. Trading Week Kicks Off With A Bang for Wal-Mart and 4 Other Stocks
  14. Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases
  15. MEI Pharma's Pracinostat Gets Breakthrough Therapy Status For Its Pracinostat In Combination With Azacitidine
  16. MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy